Lumida
/AARD
⌘K
Aardvark Therapeutics Inc

Aardvark Therapeutics Inc

AARD
$5.79USD-12.54%-0.83 today

MARKET CAP

126.2M

P/E (TTM)

FWD P/E

DAY RANGE

$6 – $6

52W RANGE

$3
$18

AI Summary

Stalk
Sell NowMedium

AARD has broken below its consolidation neckline in Stage 3 distribution, with EMAs rolling over and rising volume confirming the bearish resolve. Medium-term bias is firmly bearish, anchored by a declining 200-day SMA and a double-top breakdown. Short-term conditions remain unfavourable for longs, so we sell now on this breakdown and look to re-engage only after potential pullbacks into former support zones.

  • Unique Prader-Willi niche; ARD-101 success could unlock unmet demand
  • $73.9M cash runway to late 2027; R&D spend cut to $10.5M
  • FDA’s full clinical hold halts ARD-101 HERO/OLE trials, delaying launch
Full analysis →
Insider Trades10 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Dec 11, 2025BuyAARDNelson SunChief Financial Officer3,000$14.40$126.2M-67.73%+72.84%$43.2K+2.84%Stalk
Dec 11, 2025BuyAARDTien-Li LeeChief Executive Officer7,000$14.48$126.2M-67.73%+72.84%$101.4K+0.45%Stalk
Oct 15, 2025BuyAARDTien-Li LeeChief Executive Officer1,229$4.24$126.2M-67.73%+72.84%$5.2K+0.08%Stalk
Oct 15, 2025BuyAARDBryan JonesChief Operating Officer1,250$4.24$126.2M-67.73%+72.84%$5.3K+3.12%Stalk
Sep 15, 2025BuyAARDTien-Li LeeChief Executive Officer10,000$9.66$126.2M-67.73%+72.84%$96.6K+0.33%Stalk
Sep 10, 2025BuyAARDTien-Li LeeChief Executive Officer20,000$8.03$126.2M-67.73%+72.84%$160.7K+0.44%Stalk
Sep 9, 2025BuyAARDNelson SunChief Financial Officer6,000$8.07$126.2M-67.73%+72.84%$48.4K+6.03%Stalk
Aug 28, 2025BuyAARDTien-Li LeeChief Executive Officer17,209$4.24$126.2M-67.73%+72.84%$73.0K+1.12%Stalk
Feb 14, 2025BuyAARDNelson SunChief Financial Officer10,000$16.00$126.2M-67.73%+72.84%$160.0K+11.18%Stalk
Feb 14, 2025BuyAARDTien-Li LeeChief Executive Officer16,542$16.00$126.2M-67.73%+72.84%$264.7K+1.12%Stalk